Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these substances enhance insulin secretion and inhibit gluca

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing differences in their pha